Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers

References

• Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148–159. doi:10.1016/S0140-6736(09)60829-1
   PubMed Web of Science ®Google Scholar
• Ren P, Zou G, Bailly B, et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect. 2014;3(9):e62. doi:10.1038/emi.2014.60
   PubMedGoogle Scholar
• Albulescu IC, Kovacikova K, Tas A, Snijder EJ, van Hemert MJ. Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res. 2017;143:230–236. doi:10.1016/j.antiviral.2017.04.016
   PubMed Web of Science ®Google Scholar
• Albulescu IC, van Hoolwerff M, Wolters LA, et al. Suramin inhibits chikungunya virus replication through multiple mechanisms. Antiviral Res. 2015;121:39–46. doi:10.1016/j.antiviral.2015.06.013
   PubMed Web of Science ®Google Scholar
• Albulescu IC, White-Scholten L, Tas A, et al. Suramin inhibits chikungunya virus replication by interacting with virions and blocking the early steps of infection. Viruses. 2020;12(3):314. doi:10.3390/v12030314
   PubMed Web of Science ®Google Scholar
• Henss L, Beck S, Weidner T, et al. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Virol J. 2016;13(1):149. doi:10.1186/s12985-016-0607-2
   PubMedGoogle Scholar
• Yin W, Luan X, Li Z, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol. 2021;28(3):319–325. doi:10.1038/s41594-021-00570-0
   PubMed Web of Science ®Google Scholar
• Salgado-Benvindo C, Thaler M, Tas A, et al. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. Antimicrob Agents Chemother. 2020;64(8). doi:10.1128/AAC.00900-20
   PubMed Web of Science ®Google Scholar
• Wiedemar N, Hauser DA, Mäser P. 100 Years of Suramin. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/AAC.01168-19
   PubMed Web of Science ®Google Scholar
• Ryan C, Vokes E, Vogelzang N, Janisch L, Kobayashi K, Ratain M. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002;50(1):1–5. doi:10.1007/s00280-002-0458-y
   PubMed Web of Science ®Google Scholar
• Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin’s development: what did we learn? Invest New Drugs. 2002;20(2):209–219. doi:10.1023/a:1015666024386
   PubMed Web of Science ®Google Scholar
• Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18(7):1440–1450. doi:10.1200/JCO.2000.18.7.1440
   PubMed Web of Science ®Google Scholar
• Garcia-Schurmann JM, Schulze H, Haupt G, et al. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology. 1999;53(3):535–541. doi:10.1016/s0090-4295(98)00544-5
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol. 1995;13(9):2174–2186. doi:10.1200/JCO.1995.13.9.2174
   PubMed Web of Science ®Google Scholar
• Grossman SA, Phuphanich S, Lesser G, et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol. 2001;19(13):3260–3266. doi:10.1200/JCO.2001.19.13.3260
   PubMed Web of Science ®Google Scholar
• Naviaux RK, Curtis B, Li K, et al. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 2017;4(7):491–505. doi:10.1002/acn3.424
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Vokes EE, Vogelzang NJ, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995;13(9):2196–2207. doi:10.1200/JCO.1995.13.9.2196
   PubMed Web of Science ®Google Scholar
• Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989;7(4):499–508. doi:10.1200/JCO.1989.7.4.499
   PubMed Web of Science ®Google Scholar
• La Rocca RV, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology. 1990;40(6):954–960. doi:10.1212/wnl.40.6.954
   PubMed Web of Science ®Google Scholar
• Horne MK, Stein CA, La Rocca RV, Myers CE. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood. 1988;71(2):273–279.
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev. 1994;20(3):259–273. doi:10.1016/0305-7372(94)90003-5
   PubMed Web of Science ®Google Scholar
• Scher HI, Jodrell DI, Iversen JM, et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 1992;52(1):64–70.
   PubMed Web of Science ®Google Scholar
• Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol. 1994;12(1):166–175. doi:10.1200/JCO.1994.12.1.166
   PubMed Web of Science ®Google Scholar
• Ye L, Chen J, Fang T, et al. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health. 2021;21(1):1118. doi:10.1186/s12889-021-11198-6
   PubMed Web of Science ®Google Scholar
• Eberle RJ, Olivier DS, Amaral MS, et al. The repurposed drugs suramin and quinacrine cooperatively inhibit SARS-CoV-2 3CL(pro) in vitro. Viruses. 2021;13(5):873. doi:10.3390/v13050873
   PubMed Web of Science ®Google Scholar
• Wang Y, Qing J, Sun Y, Rao Z. Suramin inhibits EV71 infection. Antiviral Res. 2014;103:1–6. doi:10.1016/j.antiviral.2013.12.008
   PubMed Web of Science ®Google Scholar